Please assess the completion status of the following clinical trial:

Trial Title: Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* confirmed second-stage T.b. gambiense infection : presence of the parasite in blood, lymph node fluid or CSF and \>20 white blood cells/µL in CSF. In presence of blood in the CSF, lumbar puncture must be done again or the patient cannot be included in the study (see 10.9.1).~* and of age 15 years or older.~* and resident in __________ (each site will define boundaries or maximum distance)~* and written informed consent of the patient or of a legally acceptable representative if the patient is a minor (\<18 years for both genders in Uganda and Angola, \<18 years for males and \<16 years for females in the Democratic Republic of Congo) or unable to communicate.~Exclusion Criteria:~* pregnant woman (systematic testing of women of childbearing potential)~* treated for late-stage HAT during the last 36 months. Patients previously treated for first-stage (pentamidine) can be included.~* unlikely to have access to the treatment centre or be accessible at their place of residence for 18 months after treatment~* unable to take oral medication~* suffering from conditions other than second stage HAT that seriously limit the chances of survival over 18 months time~* Severe anemia (Hb\< 5g/dl)~* Severe underlying diseases upon admission (e.g. Active tuberculosis and/or being treated for TB; Bacterial or cryptococcal meningitis; Stages 3 or 4 HIV/AIDS according to the WHO clinical definition) (WHO, 1986).~* Severe renal failure based on clinical examination combined with biochemistry if available: creatinine clearance \<20mL/min~* Severe hepatic failure based on clinical examination combined with biochemistry if available: total bilirubin \>50 µmol/L, ALAT/GPT \>70 UI/L, unless these laboratory values are determined by the investigator as likely due to conditions other than hepatic failure.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).